TNBC is given the name due to its three-fold deficiency in the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), which are considered the main treatment targets in breast cancer patients. The gene discussed is PGR; the disease is breast carcinoma.